Certificate in terms of Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals Ltd has filed a routine regulatory compliance certificate with BSE. The certificate from KFin Technologies Limited, the company's Registrar and Share Transfer Agent, confirms that details of share dematerialization and rematerialization activities for Q4 FY2026 (ending March 31, 2026) have been properly furnished to all stock exchanges where the company's shares are listed. The same certificate was submitted to both NSDL and CDSL, the two depositories in India. This filing is a mandatory quarterly requirement under SEBI regulations to ensure transparency in share dematerialization processes. No specific numbers regarding quantities of shares dematerialized were disclosed in this filing.
This is a routine procedural filing with no direct impact on the stock price or shareholder value. It simply confirms the company is compliant with SEBI regulations regarding share dematerialization records.